Pfizer and BioNTech to Begin Trial of COVID Vaccine Targeted at Omicron

The firms will test immune generated by the omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of vaccine

Reuters
Reuters
Pharmacist prepares a children's dose of the Pfizer COVID-19 vaccine
Pharmacist prepares a children's dose of the Pfizer COVID-19 vaccine Credit: Charles Krupa /AP
Reuters
Reuters

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

The companies plan to test the immune response generated by the omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.

They are also testing a fourth dose of the current vaccine against a fourth dose of the omicron-based vaccine in people who received their third dose of the Pfizer/BioNTech vaccine three to six months earlier.

The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.

"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address omicron and new variants in the future," Pfizer's head of vaccine research and development, Kathrin Jansen, said in a statement.

Pfizer has said that a two-dose regimen of the original vaccine may not be sufficient to protect against infection from the omicron variant, and that protection against hospitalizations and deaths may be waning.

Still, the U.S. Centers for Disease Control and Prevention says a third dose of an mRNA vaccine like the Pfizer/BioNTech vaccine has provided 90 percent protection against hospitalization due to COVID-19.

Some countries have already started offering additional booster doses, but a recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent infection by the omicron variant.

Click the alert icon to follow topics:

Comments

SUBSCRIBERS JOIN THE CONVERSATION FASTER

Automatic approval of subscriber comments.

$1 for the first month

Already signed up? LOG IN

Protesters demonstrating in front of the consulate general of Israel in New York last year.

Huge Gap Between Young, Old Americans' View on Israel-Palestine

Rep. Henry Cuellar attends a campaign event on Wednesday, in San Antonio, Texas.

AIPAC-backed Dem Declares Victory Against Progressive Challenger in Texas Runoff

Iranian President Ebrahim Raisi and Atomic Energy Organization of Iran chief Mohammad Eslami at an event for Nuclear Technology Day in Tehran, last month.

Prospects for Reviving Iran Nuclear Deal 'Tenuous' at Best, U.S. Envoy Says

A family grieves outside the SSGT Willie de Leon Civic Center following the mass shooting at Robb Elementary School in Uvalde, Texas on Wednesday.

Israeli PM Offers Condolences After Texas Gunman Kills 21 at Elementary School

U.S. President Joe Biden, this week.

Biden Decides to Keep Iran's Revolutionary Guards on Terror List, Says Report

ADL CEO Jonathan Greenblatt.

Progressive Jews Urge ADL Chief to Apologize for Calling Out Democratic Activist